Arenavirus entry occurs through a cholesterol-dependent, non-caveolar, clathrin-mediated endocytic mechanism.
Arenaviruses are important causes of viral hemorrhagic fevers in humans. Arenavirus infection of cells occurs via a pH-dependent endocytic route, but detailed studies of entry pathways have not been done. We investigated the role of cell membrane cholesterol, caveolae, and clathrin coated pits in infection by Lassa virus (LASV), which utilizes alpha-dystroglycan (alpha-DG) as a receptor, and Pichindé virus (PICV), which does not. Depletion of cellular cholesterol by treatment with methyl betacyclodextrin (MbetaCD) or nystatin/progesterone inhibited PICV replication and transfer of packaged marker gene by LASV or PICV pseudotyped retroviral particles. In cells lacking caveolae due to silencing of the caveolin-1 gene, no inhibition of PICV infection or LASV pseudotype transduction was observed. However, PICV infection and LASV and PICV pseudotype transduction was inhibited when an Eps15 dominant negative mutant was used to inhibit clathrin-mediated endocytosis. Altogether, the results indicate that diverse arenaviruses have a common requirement for cell membrane cholesterol and clathrin mediated endocytosis in establishing infection.
Vela
Eric M
EM
Department of Pathology, Center for Biodefense and Emerging Infectious Diseases, The University of Texas Medical Branch, 301 University Blvd, Galveston, TX 77555, USA. emvela@utmb.edu
Zhang
Lihong
L
Colpitts
Tonya M
TM
Davey
Robert A
RA
Aronson
Judith F
JF
D000818:Animals; D021941:Caveolae / Q000821:virology; D051242:Caveolin 1 / Q000037:antagonists & inhibitors; D002460:Cell Line; D002522:Chlorocebus aethiops; D002784:Cholesterol / Q000096:biosynthesis; D022163:Clathrin-Coated Vesicles / Q000821:virology*; D004705:Endocytosis / Q000502:physiology*; D020868:Gene Silencing; D006801:Humans; D007836:Lassa virus / Q000502:physiology*; D008563:Membrane Lipids / Q000502:physiology*; D051379:Mice; D018052:Pichinde virus / Q000502:physiology*; D014161:Transduction, Genetic; D014709:Vero Cells; D053586:Virus Internalization; D014779:Virus Replication / Q000502:physiology
D051242:Caveolin 1; D008563:Membrane Lipids; D002784:Cholesterol
Glycoconj J. 2000 Mar-Apr;17(3 -4):143-51
11201785
J Clin Invest. 2002 Sep;110(5):597-603
12208858
Rev Med Virol. 2001 Sep-Oct;11(5):331-41
11590670
J Cell Biol. 2001 Oct 15;155(2):301-10
11604425
EMBO Rep. 2002 Jan;3(1):95-100
11751579
J Virol. 2002 Feb;76(4):1802-15
11799176
J Exp Med. 2002 Mar 4;195(5):593-602
11877482
J Virol. 2002 Apr;76(7):3267-75
11884551
J Virol. 2002 May;76(10):5140-6
11967329
Pharmacol Rev. 2002 Sep;54(3):431-67
12223531
J Biol Chem. 2002 Oct 11;277(41):38141-7
12138173
Proc Natl Acad Sci U S A. 2003 May 13;100(10):5795-800
12721375
Curr Opin Cell Biol. 2003 Aug;15(4):414-22
12892781
Virology. 2003 Nov 25;316(2):213-20
14644604
J Virol. 2004 Jan;78(1):33-41
14671085
Virology. 2004 Aug 15;326(1):6-19
15262490
Infect Immun. 1981 May;32(2):872-80
6265367
Virology. 1981 Aug;113(1):73-85
6267791
J Infect Dis. 1987 Mar;155(3):437-44
3805771
J Virol. 1987 Apr;61(4):982-5
3546729
Arch Virol. 1989;104(1-2):157-61
2923547
FEBS Lett. 1990 Aug 20;269(1):145-7
2387394
Virology. 1991 Aug;183(2):620-9
1853564
Biochim Biophys Acta. 1992 Oct 5;1110(2):202-8
1390849
Virology. 1994 Jan;198(1):1-9
8259643
Virology. 1994 Feb;198(2):455-65
8291229
Virology. 1995 May 10;209(1):3-9
7747483
Nature. 1997 Jun 5;387(6633):569-72
9177342
Virology. 2006 Apr 10;347(2):333-42
16427678
J Virol. 2006 Jun;80(12):5897-907
16731928
Virology. 2006 Jun 5;349(2):476-91
16574183
Biochem Biophys Res Commun. 2006 Aug 18;347(1):51-9
16824485
Nature. 2007 Mar 1;446(7131):92-6
17287727
J Gen Virol. 2007 Jun;88(Pt 6):1776-84
17485539
Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14764-9
9405687
J Cell Biol. 1998 Feb 9;140(3):617-26
9456321
J Cell Biol. 1998 May 18;141(4):929-42
9585412
Science. 1998 Dec 11;282(5396):2079-81
9851928
Annu Rev Cell Dev Biol. 1998;14:111-36
9891780
Tissue Antigens. 1999 Jan;53(1):33-40
10082429
J Cell Sci. 1999 May;112 ( Pt 9):1303-11
10194409
J Virol. 1999 May;73(5):4272-8
10196324
Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):6775-80
10359788
Am J Trop Med Hyg. 1999 Aug;61(2):220-5
10463670
Traffic. 2004 Dec;5(12):979-92
15522099
J Virol. 2005 Jan;79(2):756-63
15613303
J Virol. 2005 Jan;79(2):918-26
15613320
J Cell Biol. 2005 Jan 31;168(3):477-88
15668298
J Virol. 2005 May;79(10):5979-87
15857984
J Biol Chem. 2005 May 6;280(18):18015-24
15728588
Virology. 2005 Jul 20;338(1):53-60
15936793
J Virol. 2005 Aug;79(15):9862-71
16014947
Ann Med. 2005;37(6):394-403
16203612
Virol J. 2005;2:36
15840168
Biochim Biophys Acta. 2005 Dec 30;1746(3):234-51
16368465
J Gen Virol. 2006 Mar;87(Pt 3):673-8
16476990
Cell. 2006 Feb 24;124(4):729-40
16497584
J Virol. 2006 Apr;80(8):4174-8
16571833
JAMA. 2002 May 8;287(18):2391-405
11988060
Glycoconj J. 2000 Jul-Sep;17(7-9):627-47
11421354